Therefore, this work warrants further investigation of FASN as a potential target for CRC prevention in the setting of more complex models when CRC is driven by mutations other than the Apc gene to further confirm the potential for use of FASN-targeted therapy in individuals who have a high risk based on either genetics or screening colonoscopy results. The gene discussed is APC; the disease is colorectal carcinoma.